» Follicular Lymphoma Review Paper Published in The Oncologist

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Follicular Lymphoma Review Paper Published in The Oncologist

A review paper ‘Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs’ authored by LYMPHOMA CONNECT members A review paper ‘Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs’ authored by LYMPHOMA CONNECT members

Prof. Alexey V Danilov, Assoc. Prof. Loretta Nastoupil, Dr. Matthew J. Matasar, Prof. Daniel Perksy, Dr. Massimo Magagnoli, Assoc. Prof. Stefan K Barta, Prof. Paul M Barr, Assoc. Prof. Tycel Phillips, Dr. Jessica Okosun, Prof. Mats Jerkeman, Prof. Stefano Luminari, Dr. Brian Hill

Access the paper and download the slides

Prof. Alexey V Danilov

Haematologist

City of Hope National Medical Center

United States (US)

Assoc. Prof. Loretta Nastoupil

Haematologist

MD Anderson Cancer Center

United States (US)

Dr. Matthew J. Matasar

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

Prof. Daniel Perksy

Haematologist-Oncologist

University of Arizona College of Medicine

United States (US)

Dr. Massimo Magagnoli

Haematologist

Humanitas Cancer Center

Italy

Assoc. Prof. Stefan K Barta

Haematologist-Oncologist

University of Pennsylvania

United States (US)

Prof. Paul M Barr

Haematologist/Oncologist

University of Rochester Medical Center

United States (US)

Assoc. Prof. Tycel Phillips

Haematologist-Oncologist

University of Michigan Rogel Cancer Center

United States (US)

Dr. Jessica Okosun

Clinician Scientist/Haematologist

Barts Cancer Institute and St Bartholomew's Hospital

United Kingdom (UK)

Prof. Mats Jerkeman

Medical Oncologist

Lund University

Sweden

Prof. Stefano Luminari

Haematologist

University of Modena and Reggio Emilia

Italy

Dr. Brian Hill

Haematologist-Oncologist

Cleveland Clinic Taussig Cancer Institute

United States (US)

Prof. Alexey V Danilov

Haematologist

City of Hope National Medical Center

United States (US)

Alexey V. Danilov, MD, PhD, is a Professor of Medicine at the City of Hope National Medical Center, in Los Angeles, CA. He earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, Massachusetts. Dr. Danilov runs an independently funded clinical/translational program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics. He spearheads a translational and early-phase therapeutics effort in B-cell malignancies at the Knight Cancer Institute. In the laboratory, he focuses on targeting stromal-mediated pro-survival signaling in lymphoid malignancies. He has characterized promising therapeutic agents with regard to their mechanism of action and resistance, ushering them into early-phase clinical trials in CLL and NHL. He seeks to translate his findings to clinical care by developing protocols that advance current treatment paradigms. His work has received support from the Leukemia & Lymphoma Society, Lymphoma Research Foundation, the National Cancer Institute, and the Southwest Oncology Group, among other funding organizations. He has been published in numerous peer-reviewed journals including Clinical Cancer Research, Cancer Research, Haematologica, Molecular Cancer Therapeutics, Journal of Immunology and others. Among numerous speaking engagements, Dr. Danilov has chaired sessions at the American Society of Hematology Annual Meetings, and has given visiting professor lectures in London and New York. He is a member of the American Society of Hematology and the European Hematology Association. Dr. Danilov is a Leukemia & Lymphoma Society Scholar in Clinical Research and a Lymphoma Research Foundation Clinical Investigator.

Prof. Alexey V Danilov has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Assoc. Prof. Loretta Nastoupil

Haematologist

MD Anderson Cancer Center

United States (US)

Loretta Nastoupil, MD, completed her undergraduate degree at Texas Tech Health Sciences Center, graduating summa cum laude in 2003. She obtained her medical degree from the University of Texas Southwestern Medical School at Dallas in 2007. Dr. Nastoupil completed her internship and internal medicine residency at Washington University, Barnes-Jewish Hospital in St. Louis, Missouri. Following residency, she completed a hematology-medical oncology fellowship at Emory University, serving as chief fellow her last year. Dr. Nastoupil joined the faculty at MD Anderson Cancer Center in 2013 as an assistant professor in the Department of Lymphoma/Myeloma. Dr. Nastoupil is a clinical researcher with a focus on lymphoma epidemiology and outcomes. The goal of her research is to identify risk factors associated with lymphoma and eliminate disparities in outcomes to improve survival for all patients with lymphoma. She is actively involved in early phase drug development as well as immune therapy studies in indolent lymphoma. She is also actively exploring predictive biomarkers with modern therapy in lymphoma.

Assoc. Prof. Loretta Nastoupil has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Assoc. Prof. Stefan K Barta

Haematologist-Oncologist

University of Pennsylvania

United States (US)

Stefan K. Barta, MD, MRCP(UK) underwent medical training at the Johann Wolfgang Goethe University Frankfort, Germany. He completed his internal medicine training at the St. Bartholomew’s and The Royal London Hospital, UK and his hematology-oncology fellowship at the Montefiore Medical Center/Albert-Einstein College of Medicine, Bronx, New York. Previously, Dr. Barta led the T-cell lymphoma program at the Fox Chase Cancer Center. He is currently an Associate Professor of Medicine at the University of Pennsylvania, and is in charge of the T Cell Lymphoma Program. His research interests are focused on novel therapies in T-cell and other aggressive lymphomas. He was awarded with an American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010. Since then, he has led and/or developed multiple investigational clinical trials for lymphoma either as study chair, principal investigator or site principal investigator. He serves on the lymphoma committees for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and AIDS Malignancy Consortium (AMC) and is a member of the AMC steering committee. He is reviewer for several oncological journals and is on the editorial board for “Clinical Lymphoma, Myeloma & Leukemia”.

Assoc. Prof. Stefan K Barta has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Jessica Okosun

Clinician Scientist/Haematologist

Barts Cancer Institute and St Bartholomew's Hospital

United Kingdom (UK)

Dr Jessica Okosun is a Cancer Research UK Clinician Scientist at the Barts Cancer Institute and an Honorary Consultant Haematologist at St Bartholomew’s Hospital, London UK, specialising in lymphomas. She received her BA in Natural Sciences (Pathology) and qualified in medicine from the University of Cambridge in 2004. She was a recipient of the Kay Kendall Leukaemia Fund’s Junior Research Fellowship, completing her PhD in 2015 from Queen Mary, University of London. Her research interests are focussed on understanding the origin, heterogeneity and evolution of lymphomas, particularly follicular lymphomas, in a bid to define novel biomarkers and therapeutic strategies. Her research has led to several awards including the EHA/ASH Translational Research Training in Haematology award and the UK’s Royal College of Pathologist Specialty Research Medal in Haematology. She is an active member of the UK’s National Cancer Research Institute (NCRI) High Grade Lymphoma Subgroup, Hodgkin lymphoma subgroup and the Primary CNS Lymphoma (PCNSL) Working Party. She chairs the Barts Cancer Centre’s Patient and Public Research Advisory Group.

Dr. Jessica Okosun has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Stefano Luminari

Haematologist

University of Modena and Reggio Emilia

Italy

Prof Stefano Luminari is Hematologist, Associate professor of Medical Oncology at the University of Modena and Reggio Emilia, in Italy. He is head of the clinical research program for oncohematologic disorders at the Reggio Emilia research Hospital. His activity has been mainly focused on several aspects of clinical research in malignant lymphomas. In particular he is an expert in biomarkers and prognostic studies, in phase II and III clinical trials, and in population based studies. He is an active member of the Fondazione Italiana Linfomi with a leading role in the Indolent lymphoma committee and with a role as PI or co-investigator in several clinical trials mainly focused on follicular lymphomas, Hodgkin lymphomas, aggressive lymphomas (mainly elderly patients) and in the use of PET in lymphomas. He has authored more than 130 peer reviewed manuscripts. Of note, his contribution in the study of FDG-PET in Follicular Lymphoma in the staging (Luminari et al Ann Oncol 2013) and restaging assessment after induction therapy (Luminari et al. Ann Oncol 2014, Trotman J et al. Lancet Hematol 2014) and in the integration of PET with minimal residual disease in the phase of response assessment (Luminari Haematologia 2015). He is active in communicating research data and opinions through social networks (twitter account @stefanoluminari)

Prof. Stefano Luminari has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 0 min | 2019

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

DOWNLOAD THE SLIDES

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.

Other programmes of interest

Joanne Pearson

Dr Mansoor Raza Mirza

Mrs Melanie O'Neill

Connect

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.